• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>GlaxoSmithKline PLC ADR

GlaxoSmithKline PLC ADR

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. GlaxoSmithKline COPD Triple Combination Study Shows Improved Lung Function Vs Rival

    GlaxoSmithKline COPD Triple Combination Study Shows Improved Lung Function Vs Rival

  2. Global Cancer Drug News Issue 2016 - Oncology Performance Validates Strong Focus - Research and Markets

    Global Cancer Drug News Issue 2016 - Oncology Performance Validates Strong Focus - Research and Markets

  3. ADRs End Mostly Higher; Bradesco, Petrobras Rise

    ADRs End Mostly Higher; Bradesco, Petrobras Rise

  4. UPDATE: 4 powerful reasons to get into British markets now, before the Brexit vote

    UPDATE: 4 powerful reasons to get into British markets now, before the Brexit vote

  5. UPDATE: 4 powerful reasons to get into British markets now, before the Brexit vote

    UPDATE: 4 powerful reasons to get into British markets now, before the Brexit vote

  6. Global Weight Loss Supplement Market 2016-2020 - Consumers Opting for Fitness Programs & Healthy Food Consumption - Research and Markets

    Global Weight Loss Supplement Market 2016-2020 - Consumers Opting for Fitness Programs & Healthy Food Consumption - Research and Markets

  7. Low-Cost Exposure to U.S. Healthcare Firms

    This ETF holds a swath of large- and mid-cap U.S. healthcare companies.

  8. Common Questions (and Answers) for Uncommon Markets

    Five frequently asked questions for shell-shocked fund investors.

  9. Avoid Medicare Advantage Plans

    GlaxoSmithKline GSK reported solid second-quarter results on Wednesday that were largely in line with our expectations, and we don't anticipate any changes to our fair value estimate. Sales increased 10% from the prior year driven by strong sales of asthma medicine Advair, diabetes medicine ...

  10. Our 2014 Big Pharma Pipeline Rankings: Who Came Out on Top?

    Merck's reinvigorated pipeline and Sanofi's minimal patent-loss exposure placed them atop our rankings this year, while GlaxoSmithKline joined Pfizer toward the bottom.

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.